Evaluation of the potential interaction between daclatasvir and MK 5172 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2013
Price : $35 *
At a glance
- Drugs Daclatasvir (Primary) ; Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 21 Oct 2013 New trial record
- 01 Oct 2013 Results will be presented at the 64th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD) according to a Bristol-Myers Squibb media release.